ERBB2 and breast carcinoma: Hao et al. proposed the use of nanoceria to sensitise Herceptin-resistant HER2 + breast cancer cells to Herceptin therapy, which is a monoclonal antibody targeting epidermal growth factor receptor 2 (HER2) proto-oncogene found overexpressed in 20–25% of breast tumours [77, 114].